| Literature DB >> 35016027 |
Melita Irving1, Vincent Zoete2, Michal Bassani-Sternberg3, George Coukos3.
Abstract
A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.Entities:
Mesh：
Year: 2022 PMID： 35016027 DOI： 10.1016/j.ccell.2021.12.011
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743